Current and Future Directions for Angiosarcoma Therapy

  • Vaia Florou
  • Breelyn A. Wilky
Sarcoma (SH Okuno, Section Editor)
Part of the following topical collections:
  1. Topical Collection on Sarcoma

Opinion statement

Angiosarcomas are rare vascular neoplasms that are among the most aggressive subtypes of soft tissue sarcomas. Surgical resection is often challenging even in localized disease, as the infiltrative nature of these cancers leads to frequent local and metastatic recurrences. Cytotoxic chemotherapy, including anthracycline-based regimens and taxanes can produce significant responses in a subset of patients but durability is limited with most patients ultimately succumbing to metastatic disease. Targeted therapy with tyrosine kinase inhibitors is usually well-tolerated but prone to development of resistance. Few head-to-head trials have addressed the optimal sequence of therapies, or demonstrated conclusive benefits of one therapy over another based on clinical and etiologic factors. Novel therapies in clinical trials, including antibodies to endoglin and checkpoint inhibitors have demonstrated exciting early activity in patients with angiosarcoma. Improved understanding of the genetic heterogeneity within various angiosarcoma subtypes may identify predictive biomarkers to match patients to effective existing and future therapies. Overall, angiosarcoma patients with optimal performance status are best served in clinical trials that incorporate novel combinations of cytotoxic chemotherapy, targeted therapies, and immunotherapies.


Angiosarcoma Targeted therapy Chemotherapy Clinical trials Immunotherapy 


Compliance with Ethical Standards

Conflict of Interest

Vaia Florou declares that she has no conflict of interest.

Breelyn A. Wilky has received research support through a grant from Merck, and has received compensation from Novartis, Janssen Oncology, and Lilly for service as a consultant.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

References and Recommended Reading

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    Breiteneder-Geleff S, Soleiman A, Kowalski H, et al. Angiosarcomas express mixed endothelial phenotypes of blood and lymphatic capillaries: podoplanin as a specific marker for lymphatic endothelium. Am J Pathol. 1999;154:385–94.CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Antonescu C. Malignant vascular tumors—an update. Mod Pathol. 2014;27:S30–8.CrossRefPubMedGoogle Scholar
  3. 3.
    Rouhani P, Fletcher CDM, Devesa SS, Toro JR. Cutaneous soft tissue sarcoma incidence patterns in the U.S.: an analysis of 12,114 cases. Cancer. 2008;113:616–27.CrossRefPubMedGoogle Scholar
  4. 4.
    Pawlik TM, Paulino AF, McGinn CJ, Baker LH, Cohen DS, Morris JS, et al. Cutaneous angiosarcoma of the scalp: a multidisciplinary approach. Cancer. 2003;98:1716–26.CrossRefPubMedGoogle Scholar
  5. 5.
    Deyrup AT, McKenney JK, Tighiouart M, Folpe AL, Weiss SW. Sporadic cutaneous angiosarcomas: a proposal for risk stratification based on 69 cases. Am J Surg Pathol. 2008;32:72–7.CrossRefPubMedGoogle Scholar
  6. 6.
    Lahat G, Dhuka AR, Hallevi H, et al. Angiosarcoma: clinical and molecular insights. Ann Surg. 2010;251:1098–106.CrossRefPubMedGoogle Scholar
  7. 7.
    Holden CA, Spittle MF, Jones EW. Angiosarcoma of the face and scalp, prognosis and treatment. Cancer. 1987;59:1046–57.CrossRefPubMedGoogle Scholar
  8. 8.
    Young RJ, Brown NJ, Reed MW, Hughes D, Woll PJ. Angiosarcoma. Lancet Oncol. 2010;11:983–91.CrossRefPubMedGoogle Scholar
  9. 9.
    Mark RJ, Poen JC, Tran LM, Fu YS, Juillard GF. Angiosarcoma: a report of 67 patients and a review of the literature. Cancer. 1996;77:2400–6.CrossRefPubMedGoogle Scholar
  10. 10.
    Sher T, Hennessy BT, Valero V, Broglio K, Woodward WA, Trent J, et al. Primary angiosarcomas of the breast. Cancer. 2007;110:173–8.CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    • Antonescu CR, Yoshida A, Guo T, Chang N-E, Zhang L, Agaram NP, et al. KDR activating mutations in human angiosarcomas are sensitive to specific kinase inhibitors. Cancer Res. 2009;69:7175–9. Potential biomarkers for future therapy of angiosarcomas.CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Guo T, Zhang L, Chang N-E, Singer S, Maki RG, Antonescu CR. Consistent MYC and FLT4 gene amplification in radiation-induced angiosarcoma but not in other radiation-associated atypical vascular lesions. Genes Chromosom Cancer. 2011;50:25–33.CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    • Behjati S, Tarpey PS, Sheldon H, et al. Recurrent PTPRB and PLCG1 mutations in angiosarcoma. Nat Genet. 2014;46:376–9. First studies reporting results of whole exome sequencing of angiosarcomas.CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    • Ravi V, Ramesh N, Patnana M, et al. Whole-exome and targeted sequencing of angiosarcomas: target identification and treatment implications. J Clin Oncol. 2014 p 32:5s (suppl; abstr 10512). First studies reporting results of whole exome sequencing of angiosarcomas.Google Scholar
  15. 15.
    Morrison WH, Byers RM, Garden AS, Evans HL, Ang KK, Peters LJ. Cutaneous angiosarcoma of the head and neck. A therapeutic dilemma. Cancer. 1995;76:319–27.CrossRefPubMedGoogle Scholar
  16. 16.
    Rubin BP, Antonescu CR, Gannon FH, et al. Protocol for the examination of specimens from patients with tumors of bone. Arch Pathol Lab Med. 2010;134:e1–7.PubMedGoogle Scholar
  17. 17.
    Abraham JA, Hornicek FJ, Kaufman AM, et al. Treatment and outcome of 82 patients with angiosarcoma. Ann Surg Oncol. 2007;14:1953–67.CrossRefPubMedGoogle Scholar
  18. 18.
    Lahat G, Dhuka AR, Lahat S, Smith KD, Pollock RE, Hunt KK, et al. Outcome of locally recurrent and metastatic angiosarcoma. Ann Surg Oncol. 2009;16:2502–9.CrossRefPubMedGoogle Scholar
  19. 19.
    Bernstein JM, Irish JC, Brown DH, Goldstein D, Chung P, Razak ARA, et al. Survival outcomes for cutaneous angiosarcoma of the scalp versus face. Head Neck. 2017;39:1205–11.CrossRefPubMedGoogle Scholar
  20. 20.
    Ogawa K, Takahashi K, Asato Y, et al. Treatment and prognosis of angiosarcoma of the scalp and face: a retrospective analysis of 48 patients. Br J Radiol. 2012;85:1127–33.CrossRefGoogle Scholar
  21. 21.
    Singla S, Papavasiliou P, Powers B, Gaughan J, Von Mehren M, Watson JC, et al. Challenges in the treatment of angiosarcoma: a single institution experience. Am J Surg. 2014;208:254–9.CrossRefPubMedGoogle Scholar
  22. 22.
    Buehler D, Rice SR, Moody JS, Rush P, Hafez G-R, Attia S, et al. Angiosarcoma outcomes and prognostic factors: a 25-year single institution experience. Am J Clin Oncol. 2014;37:473–9.CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Fayette J, Martin E, Piperno-Neumann S, Le Cesne A, Robert C, Bonvalot S, et al. Angiosarcomas, a heterogeneous group of sarcomas with specific behavior depending on primary site: a retrospective study of 161 cases. Ann Oncol. 2007;18:2030–6.CrossRefPubMedGoogle Scholar
  24. 24.
    Fury MG, Antonescu CR, Van Zee KJ, Brennan MF, Maki RG. A 14-year retrospective review of angiosarcoma: clinical characteristics, prognostic factors, and treatment outcomes with surgery and chemotherapy. Cancer J. 2005;11:241–7.CrossRefPubMedGoogle Scholar
  25. 25.
    D’Angelo SP, Munhoz RR, Kuk D, et al. Outcomes of systemic therapy for patients with metastatic angiosarcoma. Oncology. 2015;89:205–14.CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    •• Young RJ, Natukunda A, Litière S, Woll PJ, Wardelmann E, Van Der Graaf WTA. First-line anthracycline-based chemotherapy for angiosarcoma and other soft tissue sarcoma subtypes: pooled analysis of eleven European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group trials. Eur J Cancer. 2014;50:3178–86. Standard of care regimen for angiosarcoma.CrossRefPubMedGoogle Scholar
  27. 27.
    •• Tap WD, Jones RL, Van Tine BA, et al. Olaratumab and doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma: an open-label phase 1b and randomised phase 2 trial. Lancet. 2016;388:488–97. New standard of care in the treatment of metastatic sarcomas.CrossRefPubMedPubMedCentralGoogle Scholar
  28. 28.
    Skubitz KM, Haddad PA. Paclitaxel and pegylated-liposomal doxorubicin are both active in angiosarcoma. Cancer. 2005;104:361–6.CrossRefPubMedGoogle Scholar
  29. 29.
    •• Penel N, Bui BN, Bay JO, et al. Phase II trial of weekly paclitaxel for unresectable angiosarcoma: the ANGIOTAX study. J Clin Oncol. 2008;26:5269–74. Standard of care study for angiosarcoma.CrossRefPubMedGoogle Scholar
  30. 30.
    Schlemmer M, Reichardt P, Verweij J, Hartmann JT, Judson I, Thyss A, et al. Paclitaxel in patients with advanced angiosarcomas of soft tissue: a retrospective study of the EORTC soft tissue and bone sarcoma group. Eur J Cancer. 2008;44:2433–6.CrossRefPubMedGoogle Scholar
  31. 31.
    Fata F, O’Reilly E, Ilson D, Pfister D, Leffel D, Kelsen DP, et al. Paclitaxel in the treatment of patients with angiosarcoma of the scalp or face. Cancer. 1999;86:2034–7.CrossRefPubMedGoogle Scholar
  32. 32.
    Hamerlik P, Lathia JD, Rasmussen R, et al. Autocrine VEGF–VEGFR2–Neuropilin-1 signaling promotes glioma stem-like cell viability and tumor growth. J Exp Med. 2012;209:507–20.CrossRefPubMedPubMedCentralGoogle Scholar
  33. 33.
    Itakura E, Yamamoto H, Oda Y, Tsuneyoshi M. Detection and characterization of vascular endothelial growth factors and their receptors in a series of angiosarcomas. J Surg Oncol. 2008;97:74–81.CrossRefPubMedGoogle Scholar
  34. 34.
    Zietz C, Rössle M, Haas C, Sendelhofert A, Hirschmann A, Stürzl M, et al. MDM-2 oncoprotein overexpression, p53 gene mutation, and VEGF up-regulation in angiosarcomas. Am J Pathol. 1998;153:1425–33.CrossRefPubMedPubMedCentralGoogle Scholar
  35. 35.
    Agulnik M, Yarber JL, Okuno SH, von Mehren M, Jovanovic BD, Brockstein BE, et al. An open-label, multicenter, phase II study of bevacizumab for the treatment of angiosarcoma and epithelioid hemangioendotheliomas. Ann Oncol. 2013;24:257–63.CrossRefPubMedGoogle Scholar
  36. 36.
    Ray-Coquard IL, Domont J, Tresch-Bruneel E, et al. Paclitaxel given once per week with or without bevacizumab in patients with advanced angiosarcoma: A randomized phase II trial. J Clin Oncol. 2015;33:2797–802.CrossRefPubMedGoogle Scholar
  37. 37.
    Maki RG, Wathen JK, Patel SR, et al. Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: results of sarcoma alliance for research through collaboration study 002. J Clin Oncol. 2007;25:2755–63.CrossRefPubMedGoogle Scholar
  38. 38.
    Pautier P, Floquet A, Penel N, et al. Randomized multicenter and stratified phase II study of gemcitabine alone versus gemcitabine and docetaxel in patients with metastatic or relapsed leiomyosarcomas: a Federation Nationale des Centres de Lutte Contre le Cancer (FNCLCC) French Sarcoma Group. Oncologist. 2012;17:1213–20.CrossRefPubMedPubMedCentralGoogle Scholar
  39. 39.
    Stacchiotti S, Palassini E, Sanfilippo R, et al. Gemcitabine in advanced angiosarcoma: a retrospective case series analysis from the Italian rare cancer network. Ann Oncol. 2012;23:501–8.CrossRefPubMedGoogle Scholar
  40. 40.
    Dickson MA, D’Adamo DR, Keohan ML, et al. Phase II trial of gemcitabine and docetaxel with bevacizumab in soft tissue sarcoma. Sarcoma. 2015;2015:532,478.CrossRefGoogle Scholar
  41. 41.
    Penel N, Italiano A, Ray-coquard I, et al. Metastatic angiosarcomas: doxorubicin-based regimens, weekly paclitaxel and metastasectomy significantly improve the outcome. Ann Oncol. 2012;23:517–23.CrossRefPubMedGoogle Scholar
  42. 42.
    Italiano A, Cioffi A, Penel N, et al. Comparison of doxorubicin and weekly paclitaxel efficacy in metastatic angiosarcomas. Cancer. 2012;118:3330–6.CrossRefPubMedGoogle Scholar
  43. 43.
    Maki RG, D’Adamo DR, Keohan ML, et al. Phase II study of sorafenib in patients with metastatic or recurrent sarcomas. J Clin Oncol. 2009;27:3133–40.CrossRefPubMedPubMedCentralGoogle Scholar
  44. 44.
    Ray-Coquard I, Italiano A, Bompas E, et al. Sorafenib for patients with advanced angiosarcoma: a phase II trial from the French Sarcoma Group (GSF/GETO). Oncologist. 2012;17:260–6.CrossRefPubMedPubMedCentralGoogle Scholar
  45. 45.
    Kollár A, Jones RL, Stacchiotti S, et al. Pazopanib in advanced vascular sarcomas: an EORTC Soft Tissue and Bone Sarcoma Group (STBSG) retrospective analysis. Acta Oncol (Madr). 2017;56:88–92.CrossRefGoogle Scholar
  46. 46.
    van der Graaf WT, Blay J-Y, Chawla SP, et al. Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2012;379:1879–86.CrossRefPubMedGoogle Scholar
  47. 47.
    Yoo KH, Kim ST, Lee J, Park SH, Kim SJ, Kim HS. The role of pazopanib in various histologic subtypes of metastatic soft tissue sarcomas. J Clin Oncol. 2014;32:10586.CrossRefGoogle Scholar
  48. 48.
    Ogata D, Yanagisawa H, Suzuki K, Oashi K, Yamazaki N, Tsuchida T. Pazopanib treatment slows progression and stabilizes disease in patients with taxane-resistant cutaneous angiosarcoma. Med Oncol. 2016;33:116.CrossRefPubMedGoogle Scholar
  49. 49.
    Yoo C, Kim J-E, Yoon S-K, Kim SC, Ahn J-H, Kim TW, et al. Angiosarcoma of the retroperitoneum: report on a patient treated with sunitinib. Sarcoma. 2009;2009:360875.CrossRefPubMedPubMedCentralGoogle Scholar
  50. 50.
    Silva E, Gatalica Z, Vranic S, Basu G, Reddy SK, Voss A. Refractory angiosarcoma of the breast with VEGFR2 upregulation successfully treated with sunitinib. Breast J. 2015;21:205–7.CrossRefPubMedGoogle Scholar
  51. 51.
    Mir O, Brodowicz T, Italiano A, et al. Safety and efficacy of regorafenib in patients with advanced soft tissue sarcoma (REGOSARC): a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Oncol. 2016;17:1732–42.CrossRefPubMedGoogle Scholar
  52. 52.
    Stiles JM, Amaya C, Rains S, et al. Targeting of beta adrenergic receptors results in therapeutic efficacy against models of hemangioendothelioma and angiosarcoma. PLoS One. 2013;8:e60021.CrossRefPubMedPubMedCentralGoogle Scholar
  53. 53.
    Daguzé J, Saint-Jean M, Peuvrel L, Cassagnau E, Quéreux G, Khammari A, et al. Visceral metastatic angiosarcoma treated effectively with oral cyclophosphamide combined with propranolol. JAAD Case Rep. 2016;2:497–9.CrossRefPubMedPubMedCentralGoogle Scholar
  54. 54.
    Daguzé J, Saint-Jean M, Dréno B. Large nose angiosarcoma treated effectively with oral cyclophosphamide combined with propranolol. J Eur Acad Dermatol Venereol. 2017;12:3218–21.Google Scholar
  55. 55.
    Banavali S, Pasquier E, Andre N. Targeted therapy with propranolol and metronomic chemotherapy combination: sustained complete response of a relapsing metastatic angiosarcoma. Ecancermedicalscience. 2015;9:499.CrossRefPubMedPubMedCentralGoogle Scholar
  56. 56.
    Pasquier E, André N, Street J, et al. Effective management of advanced angiosarcoma by the synergistic combination of propranolol and vinblastine-based metronomic chemotherapy: a bench to bedside study. EBioMedicine. 2016;6:87–95.CrossRefPubMedPubMedCentralGoogle Scholar
  57. 57.
    Chow W, Amaya CN, Rains S, Chow M, Dickerson EB, Bryan BA. Growth attenuation of cutaneous angiosarcoma with propranolol-mediated β-blockade. JAMA Dermatol. 2015;151:1226–9.CrossRefPubMedGoogle Scholar
  58. 58.
    Sankhala KK, Attia S, Barve M, Wright J, Riedel R, Robinson S, et al. TRC105 (endoglin antibody) in combination with pazopanib in patients with advanced angiosarcoma. In: Connect. Tissue Oncol. Soc. p Poster 110. 2016.Google Scholar
  59. 59.
    • Tawbi HA, Burgess M, Bolejack V, et al. Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial. Lancet Oncol. 2017;2045:1–9. First trial on the efficacy of checkpoint inhibition in advanced soft tissue and bone sarcomas.Google Scholar
  60. 60.
    Sindhu S, Gimber LH, Cranmer L, McBride A, Kraft AS. Angiosarcoma treated successfully with anti-PD-1 therapy—a case report. J Immunother Cancer. 2017;5:58.CrossRefPubMedPubMedCentralGoogle Scholar
  61. 61.
    Wilky BA, Kumthekar P, Wesolowski R, et al. Phase 1 open-label, multiple ascending dose trial of AGEN1884, an anti-CTLA-4 monoclonal antibody, in advanced solid malignancies. J Clin Oncol. 2017;35:3075.CrossRefGoogle Scholar
  62. 62.
    Somaiah N, Anthony C, Lin H, et al. A phase II multi-arm study to test the efficacy of immunotherapeutic agents in multiple sarcoma subtypes. In: Connect. Tissue Oncol. Soc. p Paper 010. 2017.Google Scholar
  63. 63.
    Angiosarcoma Project.

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  1. 1.University of Miami Sylvester Comprehensive Cancer CenterMiamiUSA

Personalised recommendations